ReviewNature reviews. Rheumatology2014
Paraneoplastic syndromes in rheumatology.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 148 citations in OpenAlex.
- A platform for parallel TCR cloning and testing enables anti-neoantigen tumor immunotherapy.JCI insight · 2026Article
- Dermatomyositis as a Paraneoplastic Syndrome of Metastatic Urothelial Carcinoma.Current oncology (Toronto, Ont.) · 2026Article
- Paraneoplastic systemic lupus erythematosus associated with dysgerminoma: a case report and literature review.Internal and emergency medicine · 2025Review
- Castleman's disease in the rheumatological practice.Zeitschrift fur Rheumatologie · 2024Review
- Article
- Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.Annals of the rheumatic diseases · 2024Article
- [Castleman's disease in the rheumatological practice].Zeitschrift fur Rheumatologie · 2024Review
- Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review.Advances in rheumatology (London, England) · 2024Article
- Article
- Cardiac sarcoma presenting as paraneoplastic arthritis and clubbing: a case report and literature review.BMC rheumatology · 2023Article
- Seronegative enthesoarthritis as the first presentation of the atrial myxoma.Rheumatology and immunology research · 2023Article
- Absence of Long-Lasting Morning Stiffness at the Time of Diagnosis as Paraneoplastic Warning in Patients with Polymyalgia Rheumatica (PMR): Data from Italian Single-Center Study.Life (Basel, Switzerland) · 2023Article
- [Paraneoplastic syndromes in rheumatology].Zeitschrift fur Rheumatologie · 2023Review
- Atypical Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in an Elderly Lung Cancer Patient.Maedica · 2023Article
- Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome as a Manifestation of Recurrent Ovarian Cancer.Internal medicine (Tokyo, Japan) · 2023Article
- Paraneoplastic dermatomyositis associated with urothelial cancer: report of a case and systematic review of the literature.Frontiers in oncology · 2023Review
- First case report of rheumatoid-like paraneoplastic polyarthritis in a patient with Fallopian tube cancer.Rheumatology advances in practice · 2023Article
- Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression.Biomedicines · 2022Review
- Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience.Life (Basel, Switzerland) · 2022Article
- Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma.IJU case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients that present with musculoskeletal symptoms, diagnostic procedures carried out by physicians and rheumatologists are primarily aimed at confirming or excluding the occurrence of primary rheumatic diseases. Another important trigger for musculoskeletal disease, however, is the presence of a tumour. Careful clinical investigation and knowledge of the gestalt of musculoskeletal syndromes related to respective tumour entities is of utmost importance for the diagnosis of paraneoplastic rheumatic diseases such as hypertrophic osteoarthropathy, paraneoplastic polyarthritis, RS3PE syndrome, palmar fasciitis and polyarthritis, cancer-associated myositis and tumour-induced osteomalacia. This places great responsibility on rheumatologists in diagnosing malignancies and referring the patient for effective treatment. The selective influence of tumours on musculoskeletal tissue is surprising and indicates that tumours alter tissues such as the periosteum, synovial membrane, subcutaneous connective tissue, fascia, muscles and bones by specific molecular processes. Some of the underlying mechanisms have been unravelled, providing valuable information on the physiologic and pathophysiologic roles of mediators such as vascular endothelial growth factor and fibroblast growth factor 23.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.